Blinatumomab, a Bi-Specific Anti-Cd19/Cd3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2014.00063
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Blinatumomab in Acute Lymphoblastic Leukemia

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

Efficiency of Blinatumomab in a T(8;21) Acute Myeloid Leukemia Expressing CD19

Haematologica
Hematology
2019English

Pediatric Acute Lymphoblastic Leukemia

Hematology & Transfusion International Journal
2017English

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

Advances in Therapy
MedicinePharmacology
2019English

Outcome of Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia After Blinatumomab Failure: No Change in the Level of CD19 Expression

American Journal of Hematology
Hematology
2017English

Treatment of CD19-Positive Mixed Phenotype Acute Leukemias With Blinatumomab

American Journal of Hematology
Hematology
2018English

Correlates of Resistance and Relapse During Blinatumomab Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2017English

Potential for Bispecific T-Cell Engagers: Role of Blinatumomab in Acute Lymphoblastic Leukemia

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2016English

Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia

Clinical Journal of Oncology Nursing
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy